Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1

Journal of Clinical Investigation

Volumn 121, Issue 3, 2011, Pages 1075-1087

  Harrison, Luke R E ^a,b,c   Micha, Dimitra ^a,b,c   Brandenburg, Martin ^a,b,c   Simpson, Kathryn L ^a,b,c   Morrow, Christopher J ^a,b,c   Denneny, Olive ^a,b,c   Hodgkinson, Cassandra ^a,b,c   Yunus, Zaira ^a,b,c   Dempsey, Clare ^a,b,c   Roberts, Darren ^a,b,c,d   Blackhall, Fiona ^a,b,c,e   Makin, Guy ^a,b,c,d   Dive, Caroline ^a,b,c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b University of Manchester   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; CISPLATIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN MCL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL HYPOXIA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HYPOXIC CELL; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NITROPHENOLS; PEPTIDE FRAGMENTS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 79952238495     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43505     Document Type: Article

References (44)

1. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 1987;5(4):313-341.
2. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15(4):678-685. (Pubitemid 351405072)
3. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625-634.
4. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621-632.
5. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008; 27(suppl 1):S149-S157.
6. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647-656. (Pubitemid 37328916)
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
8. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer. 1991;64(1):192-196.
9. Oltersdorf T, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677-681. (Pubitemid 40825512)
10. Tse C, et al. ABT-263: a potent and orally bio-available Bcl-2 family inhibitor. Cancer Res. 2008; 68(9):3421-3428.
11. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009;16(3):360-367.
12. Hann CL, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68(7):2321-2328. (Pubitemid 351521806)
13. Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10(5):375-388. (Pubitemid 44693472)
14. van Delft MF, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389-399. (Pubitemid 44711953)
15. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007;67(2):782-791. (Pubitemid 46192219)
16. Erler JT, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol. 2004;24(7):2875-2889. (Pubitemid 38381277)
17. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61(18):6669-6673. (Pubitemid 32896483)
18. Piret JP, et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem. 2005; 280(10):9336-9344.
19. Liu XH, Yu EZ, Li YY, Kagan E. HIF-1alpha has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. J Cell Biochem. 2006;97(4):755-765.
20. Brunelle JK, et al. Loss of Mcl-1 protein and inhibition of electron transport chain together induce anoxic cell death. Mol Cell Biol. 2007;27(4):1222-1235. (Pubitemid 46239806)
21. Willis SN, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005; 19(11):1294-1305. (Pubitemid 41003019)
22. Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH. BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med. 2004;199(1):113-124.
23. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441-1454.
24. Roberts DL, et al. Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer. 2009; 101(8):1290-1297.
25. Brown LM, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol. 2006;69(2):411-418. (Pubitemid 43121938)
26. Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 2005;280(11):10491-10500. (Pubitemid 40395908)
27. Cooper S, Spiro SG. Small cell lung cancer: treatment review. Respirology. 2006;11(3):241-248.
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
29. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93(4):266-276. (Pubitemid 32219813)
30. Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990;50(11):3339-3344. (Pubitemid 20190142)
31. Zhivotovsky B, Joseph B, Orrenius S. Tumor radiosensitivity and apoptosis. Exp Cell Res. 1999; 248(1):10-17. (Pubitemid 29393924)
32. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437-447. (Pubitemid 38745529)
33. Azad MB, et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy. 2008;4(2):195-204. (Pubitemid 351231183)
34. Lai Y, et al. Activation of NFkappaB dependent apoptotic pathway in pancreatic islet cells by hypoxia. Islets. 2009;1(1):19-25.
35. Walmsley SR, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NFkappaB activity. J Exp Med. 2005;201(1):105-115. (Pubitemid 40130088)
36. Ricci MS, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007;12(1):66-80. (Pubitemid 47001783)
37. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2009; 66(8):1326-1336.
38. Shibue T, et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2003; 17(18):2233-2238. (Pubitemid 37128638)
39. Opferman JT. Unraveling MCL-1 degradation. Cell Death Differ. 2006;13(8):1260-1262. (Pubitemid 44057455)
40. Alarcon R, Koumenis C, Geyer RK, Maki CG, Giaccia AJ. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999; 59(24):6046-6051. (Pubitemid 30035618)
41. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005;121(7):1085-1095. (Pubitemid 40884398)
42. Mascaux C, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30(1):23-36.
43. Hussein D, Estlin EJ, Dive C, Makin GW. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther. 2006; 5(9):2241-2250. (Pubitemid 44530461)
44. Barraclough J, Hodgkinson C, Hogg A, Dive C, Welman A. Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. Neoplasia. 2007; 9(9):745-754. (Pubitemid 47523236)